Abstract
Objective
Our study aimed to assess the risk of in-hospital mortality due to chronic alcoholic liver disease (CALD) and other comorbidities in spontaneous bacterial peritonitis (SBP) inpatients.
Methods
We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS, 2012 to 2014) from the United States and included 6,530 patients (age 18-50 years) with a primary diagnosis of SBP. Logistic regression was used to evaluate the odds ratio (OR) for in-hospital mortality in SBP by comorbidities.
Results
The prevalence of CALD in SBP patients is 43.6%, and a higher proportion were males (68.8%) and whites (67%). Middle-aged adults (OR 2.8, 95% CI 1.74-4.45) had higher odds of in-hospital mortality in SBP patients. Race and sex were non-significant predictors for mortality risk. Patients with comorbid coagulopathy (OR 1.9, 95% CI 1.45-2.48) and heart failure (OR 3.9, 95% CI 2.46-6.36) have increased mortality in SBP inpatients. After controlling confounders, CALD was significantly associated with increased in-hospital mortality (OR 1.5, 95% CI 1.12-1.94) in SBP inpatients.
Conclusion
CALD is an independent factor in increasing the risk of in-hospital mortality in SBP patients by 48%. Alcohol use screening, and alcohol abstinence and supportive therapy need to be implemented at an earlier stage to improve health-related quality of life and reduce in-hospital mortality in SBP patients.
Keywords: spontaneous bacterial peritonitis, alcohol-related liver disease, alcohol dependence, alcohol misuse, mortality risk
Introduction
Spontaneous bacterial peritonitis (SBP) is an infection of the ascitic fluid without any previous evidence of intra-abdominal surgery [1]. SBP is diagnosed based on polymorphonuclear neutrophils higher than 250 cells per cubic millimeter [2]. The prevalence of SBP in liver cirrhosis range from 11% to 14% and the incidence of SBP in hospitalized patients ranges from 10% to 30% [3,4]. In earlier days, SBP was associated with a high mortality rate of about 70%, but due to the advancement of treatment and diagnostic paracentesis, the mortality rate in hospitalized patients has decreased to around 17.6% [4]. Some of the studies have shown a higher mortality rate in older age, female sex, and patients with complications of liver cirrhosis like hepatic encephalopathy, acute kidney injury, variceal bleed, and sepsis [4].
Alcohol consumption has increased worldwide and alcohol-related complications range from hepatic steatosis to alcoholic hepatitis to alcoholic cirrhosis and end-stage liver disease [5]. It takes about 10 years to progress, so abstinence is the best way to prevent alcohol-related diseases [6]. According to the World Health Organization (WHO), alcoholism results in 3.3 million deaths every year, which is 6% of total global annual death [7]. About 10% to 20% of patients who are heavy drinkers develop alcohol-related liver diseases [8]. About 36% of patients with chronic hepatitis have alcohol dependence or abuse problems [9]. Hospital admission in alcoholic liver disease has increased by 18.3% [10] from 2012 to 2016. Chronic alcoholic liver disease (CALD) is diagnosed with a history of heavy alcohol intake; on physical examination, a patient may have signs Dupuytren's contracture, rhinophyma, spider angioma, palmar erythema, jaundice [8]. In CALD, clinical manifestation starts late and the disease spectrum range from alcoholic hepatitis to alcoholic cirrhosis [11].
Various theories are proposed for the pathogenesis of SBP. In patients with liver disease, there is an overgrowth of bacteria in the interstitial lumen [12]. Due to various structural abnormalities like vascular congestion and edema, bacterial translocation occurs in the mesenteric lymph nodes [12]. Patients with liver disease also have decreased immune function leading to bacteria overgrowth and seepage of bacteria into the ascitic fluid [12]. Due to decreased protein levels in cirrhotic patients, low complement level, and poor phagocytic activity, it leads to further growth of bacteria in the ascitic fluid [13,14]. SBP contributes about 9.8% of bacterial infection in alcoholic liver disease [14].
SBP is associated with poor prognosis [12]. Patient survival rates are 67%, 50%, and 42% in one month, six months, and one year, respectively, after an initial diagnosis of SBP [3]. SBP is one of the most common causes of bacterial death that contributes to about 33% of in-hospital mortality due to infection [3]. SBP occurs most commonly in liver cirrhosis patients [3]. CALD, alcoholic hepatitis, hepatitis B, hepatitis C, hemochromatosis, and autoimmune hepatitis cause liver cirrhosis. One of the studies showed 48% of patients with liver cirrhosis die because of CALD [8]. So there must be some association between the in-hospital mortality in SBP and CALD. The current literature is scarce and contradictory as some studies state that acute kidney injury is the most common cause of in-hospital mortality in SBP patients while some support CALD [4,15].
In our study, we utilized the inpatient data from the United States (US) hospitals: (1) to assess the differences in demographics and comorbidities seen in inpatients for SBP by the presence of comorbid CALD, and (2) to assess the risk of in-hospital mortality due to CALD and other comorbidities in SBP inpatients.
Materials and methods
Data source
We utilized the Nationwide Inpatient Sample (NIS) data from 2012 to 2014 in our cross-sectional data analysis study. The NIS provides patient health information from about 4,400 non-federal hospitals across 44 states in the US [16]. Diagnostic information in the NIS is detected using the International Classification of Diseases, ninth edition (ICD-9) codes, and Clinical Classification Software (CCS) codes [17].
Inclusion criteria and outcome variables
We included adult patients (age 18 to 50 years) with a primary discharge diagnosis of SBP using ICD-9 code 567.23. These sample of 6,530 inpatients was further grouped by comorbid discharge diagnosis of CALD (N = 2,850) using the ICD-9 codes 571.2 or 571.3.
This study included the following demographic variables: age (18-35 and 36-50 years), sex (male or female), and race (white, black, hispanic, and others) [17]. The comorbid diagnosis of diabetes, hypertension, congestive cardiac failure (CCF), AIDS, renal failure, and coagulopathy were identified using ICD-9 or CCS diagnosis codes [17]. We measured the in-hospital mortality between CALD and non-CALD cohorts. In the NIS, in-hospital mortality is reported as all-cause and is the number of inpatient deaths [17].
Statistical analysis
We used cross-tabulation and descriptive statistics to discern the differences in demographics and comorbidities in SBP inpatients by comorbid CALD. We used a separate model of descriptive statistics to evaluate the in-hospital mortality by comorbidities. Logistic regression analysis was used to measure the odds ratio (OR) association of CALD with in-hospital mortality in SBP inpatients, and the model was controlled for demographic and other chronic comorbidities. A P-value of less than 0.01 was used to determine the statistical significance in all analyses and was conducted using the Statistical Package for the Social Sciences (SPSS), version 26 (IBM Corporation, Armonk, NY).
Ethical approval
To protect the patient's identity and their health information, the NIS used separate codes to de-identify the database. We do not require approval from the institutional review board [16].
Results
We analyzed a total sample of 6,530 inpatients hospitalized for SBP, with 43.6% having comorbid CALD. The majority of the inpatients with CALD were middle-age adults 36 to 50 years (87%) and were older than the non-CALD cohort (43.3 years vs. 40.6 years, P < 0.001). A higher proportion of CALD inpatients were male (68.8% vs. 52.6%) and white (67% vs. 51.8%) compared to the non-CALD cohort. Comorbidities were seen in a lower proportion of CALD cohort other than a statistically significant difference with comorbid coagulopathy, i.e., 51.2% in CALD versus 29.8% in the non-CALD cohort as shown in Table 1.
Table 1. Distribution of SBP inpatients by comorbid CALD.
SBP, spontaneous bacterial peritonitis; CALD, chronic alcoholic liver disease
| Variable | CALD (-) | CALD (+) | Total | P-value |
| Total (N) | 3680 | 2850 | 6530 | - |
| Mean age, years (SD) | 40.6 (8.68) | 43.3 (5.82) | - | <0.001 |
| Age at admission, in % | ||||
| 18–35 years | 24.9 | 13.0 | 19.7 | <0.001 |
| 36–50 years | 75.1 | 87.0 | 80.3 | |
| Sex, in % | ||||
| Male | 52.6 | 68.8 | 59.6 | <0.001 |
| Female | 47.4 | 31.2 | 40.4 | |
| Race, in % | ||||
| White | 51.8 | 67.0 | 58.3 | <0.001 |
| Black | 20.6 | 4.4 | 13.6 | |
| Hispanic | 19.0 | 20.3 | 19.6 | |
| Other | 8.6 | 8.3 | 8.5 | |
| Comorbidities, in % | ||||
| AIDS | 2.6 | 0.7 | 1.8 | <0.001 |
| Diabetes | 14.5 | 13.2 | 13.9 | 0.110 |
| Hypertension | 40.2 | 27.4 | 34.6 | <0.001 |
| Congestive cardiac failure | 8.0 | 3.0 | 5.8 | <0.001 |
| Coagulopathy | 29.8 | 51.2 | 39.1 | <0.001 |
| Renal failure | 29.9 | 11.6 | 21.9 | <0.001 |
| In-hospital mortality, in % | 2.7 | 6.1 | 4.2 | <0.001 |
Risk factors for in-hospital mortality in SBP
Middle-age adults (36-50 years) have 2.8 times higher odds (95% CI 1.74-4.45) compared to young adults for inpatient death during SBP management. Statistically, no significant impact was seen in in-hospital mortality based on sex distribution (P = 0.486). When compared to the whites, no other races had a statistically significant association with in-hospital mortality.
Among chronic comorbidities, CCF and coagulopathy increased the risk of in-hospital mortality in SBP inpatients by four times (95% CI 2.46-6.36) and by two times (95% CI 1.45-2.48), respectively. Hypertension and diabetes had a negative association, whereas AIDS and renal failure had a statistically non-significant association with in-hospital mortality in SBP inpatients. CALD significantly increases the risk of in-hospital mortality by 1.5 times (95% CI 1.12-1.94) compared to the non-CALD cohort after controlling for demographic and other comorbidities as shown in Table 2.
Table 2. In-hospital mortality risk factors in SBP inpatients.
SBP, spontaneous bacterial peritonitis
| Variable | Logistic regression model | |||
| Odds ratio | 95% confidence interval | P-value | ||
| Lower | Upper | |||
| Age at admission | ||||
| 18–35 years | Reference | |||
| 36–50 years | 2.78 | 1.74 | 4.45 | <0.001 |
| Sex | ||||
| Male | 1.10 | 0.84 | 1.46 | 0.486 |
| Female | Reference | |||
| Race | ||||
| White | Reference | |||
| Black | 0.52 | 0.29 | 0.92 | 0.026 |
| Hispanic | 1.03 | 0.57 | 1.13 | 0.205 |
| Other | 1.03 | 0.66 | 1.60 | 0.895 |
| Chronic alcoholic liver disease | ||||
| No | Reference | |||
| Yes | 1.48 | 1.12 | 1.94 | 0.006 |
| Comorbidities | ||||
| No comorbidity | Reference | |||
| AIDS | 1.77 | 0.69 | 4.55 | 0.236 |
| Diabetes | 0.12 | 0.05 | 0.29 | <0.001 |
| Hypertension | 0.48 | 0.33 | 0.69 | <0.001 |
| Congestive cardiac failure | 3.96 | 2.46 | 6.36 | <0.001 |
| Coagulopathy | 1.89 | 1.45 | 2.48 | <0.001 |
| Renal failure | 0.90 | 0.59 | 1.37 | 0.623 |
The highest numbers of death were seen in SBP inpatients with comorbid CALD (63.6%) followed by coagulopathy (60%) and diabetes (20%) as shown in Figure 1.
Figure 1. In-hospital mortality in SBP inpatients by comorbidities.
SBP, spontaneous bacterial peritonitis; CALD, chronic alcoholic liver disease; CCF, congestive cardiac failure
Discussion
From our analysis conducted from the inpatient data from the US hospitals, the prevalence of CALD in SBP is 43.6%, and the majority of the inpatients were adults age 36 to 50 years, which was correlated to epidemiologic data of alcohol liver disease in Korea [18]. We found that middle-age adults are at a 178% higher risk of in-hospital mortality during SBP management compared to young adults. Women are at higher risk of developing CALD than men due to environmental and genetic factors [19]. Alcohol consumption and metabolism vary by gender, and so 12-22 grams/day in women and 24-46 grams/day in men may lead to the development of CALD [20]. About three-fifths of the SBP inpatients with CALD were males, which may be possible as men consume more alcohol than women [21]. We found a non-significant relationship between sex and mortality risk in SBP patients. Our study showed that about 67% of SBP patients with CALD were whites, which are possibly due to a higher consumption of alcohol in whites compared to other races [22]. There was a statistically non-significant association with mortality risk and race in our study inpatients.
Ethanol metabolism produces reactive oxygen species that in turn activate genes for lipid biosynthesis [23]. The imbalance in the central nervous system (CNS) affects the baroreceptor leading to sympathetic overactivity and stimulation of endothelin [23]. This causes renin-angiotensin activation (RAA), which leads to a decrease in left ventricular contractility [24]. In addition to this, chronic alcoholism leads to cardiomyopathy, myocyte dysfunction, affects calcium homeostasis, malnutrition hence ultimately lead to CCF [24]. Overall, CCF was seen in 5.8% of SBP inpatients and less in those with CALD (3%), but CCF was the most prominent risk factor for mortality during SBP hospitalization.
About 60% of SBP patients with CALD had comorbid coagulopathy, and it was significantly associated with in-hospital mortality and increased the risk by 89%. SBP is common in patients with cirrhosis and ascites, and cirrhotic patients are likely to have an infection that activates cytokines like tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1 affecting circulation and coagulation pathway [25]. Therefore, coagulopathy and renal failure further deteriorate CALD. Decompensated CALD is associated with renal failure, due to the reduction of renal blood flow, which leads to vasoconstriction of the main renal and smaller arteries, which further affects cortical ischemia [26]. One of the studies using NIS data showed a 70.3% in-hospital mortality in SBP patients due to renal failure [4]. But, after controlling for potential confounder in our study, we found a non-significant association between renal failure and mortality risk. We found no significant difference in the prevalence of diabetes between CALD and non-CALD cohorts, and both hypertension and diabetes did not have a positive association with increased in-hospital mortality risk.
Using the multivariable logistic regression model in our study, we found that CALD is significantly associated with increased in-hospital mortality in SBP by 48%. SBP most commonly occurs in a patient with cirrhosis and ascites [27]. Patients with alcoholic cirrhosis are more likely to have ascites, which could contribute to hepatic decompensation in CALD patients, thereby leading to an increase in in-hospital mortality [28].
There are some limitations to our study. Firstly, we used administrative data and so the study inpatients were included based on ICD-9 codes, which may lead to underreporting of comorbid conditions, including CALD which may affect the statistical analyses. Second, it includes all-cause in-hospital mortality and so doesn’t prove a causal relationship between mortality and comorbidities in SBP. Despite this, we have tried to strengthen our study by using national data, which represents the wide range of hospitals from 44 states across the US and the results are generalized to the inpatient population.
Conclusions
Medical comorbidities like CCF and coagulopathy increases in-hospital mortality in SBP patients. Chronic alcohol intake leading to CALD was prevalent in SBP patients and was an independent factor that increases the risk of in-hospital mortality by 48%. Alcohol use screening, and alcohol abstinence and supportive therapy need to be implemented at an earlier stage to improve health-related quality of life and reduce in-hospital mortality in SBP patients.
The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained by all participants in this study
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Spontaneous bacterial peritonitis. Song DS. Korean J Gastroenterol. 2018;72:56–63. doi: 10.4166/kjg.2018.72.2.56. [DOI] [PubMed] [Google Scholar]
- 2.Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis. Ichou L, Carbonell N, Rautou PE, et al. Gut. 2016;65:536–538. doi: 10.1136/gutjnl-2015-310160. [DOI] [PubMed] [Google Scholar]
- 3.Review article: spontaneous bacterial peritonitis - bacteriology, diagnosis, treatment, risk factors and prevention. Dever JB, Sheikh MY. Aliment Pharmacol Ther. 2015;41:1116–1131. doi: 10.1111/apt.13172. [DOI] [PubMed] [Google Scholar]
- 4.Mortality from spontaneous bacterial peritonitis among hospitalized patients in the USA. Niu B, Kim B, Limketkai BN, Sun J, Li Z, Woreta T, Chen PH. Dig Dis Sci. 2018;63:1327–1333. doi: 10.1007/s10620-018-4990-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Alcoholic hepatitis: a review. Hosseini N, Shor J, Szabo G. Alcohol Alcohol. 2019;54:408–416. doi: 10.1093/alcalc/agz036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Alcoholic liver disease - the extent of the problem and what you can do about it. Hazeldine S, Hydes T, Sheron N. Clin Med (Lond) 2015;15:179–185. doi: 10.7861/clinmedicine.15-2-179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Alcoholic hepatitis: how far are we and where are we going? Prado V, Caballería J, Vargas V, Bataller R, Altamirano J. Ann Hepatol. 2016;15:463–473. [PubMed] [Google Scholar]
- 8.ACG clinical guideline: alcoholic liver disease. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. Am J Gastroenterol. 2018;113:175–194. doi: 10.1038/ajg.2017.469. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Problematic cannabis use and risk of complications in patients with chronic hepatitis C. Rashid W, Patel V, Ravat V, et al. Cureus. 2019;11:0. doi: 10.7759/cureus.5373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Trends in the burden of chronic liver disease among hospitalized US adults. Hirode G, Saab S, Wong RJ. JAMA Netw Open. 2020;3:0. doi: 10.1001/jamanetworkopen.2020.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Pathogenesis and management of alcoholic liver disease. Farooq MO, Bataller R. Dig Dis. 2016;34:347–355. doi: 10.1159/000444545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Marciano S, Díaz JM, Dirchwolf M, Gadano A. Hepat Med. 2019;11:13–22. doi: 10.2147/HMER.S164250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Toshikuni N, Arisawa T, Tsutsumi M. World J Gastroenterol. Vol. 20. Treasure Island, FL: StatPearls Publishing LLC; 2014. Nutrition and exercise in the management of liver cirrhosis; pp. 7286–7297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Clinical characteristics and prognostic impact of bacterial infection in hospitalized patients with alcoholic liver disease. Park JK, Lee CH, Kim IH, et al. J Korean Med Sci. 2015;30:598–605. doi: 10.3346/jkms.2015.30.5.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis. Wiegand J, Kühne M, Pradat P, Mössner J, Trepo C, Tillmann HL. Aliment Pharmacol Ther. 2012;35:1443–1450. doi: 10.1111/j.1365-2036.2012.05108.x. [DOI] [PubMed] [Google Scholar]
- 16.Overview of the National (Nationwide) Inpatient Sample. [Mar;2020 ];https://www.hcup-us.ahrq.gov/nisoverview.jsp 2019
- 17.NIS Description of Data Elements. [Mar;2020 ];https://www.hcup-us.ahrq.gov/db/nation/nis/nisdde.jsp 2019
- 18.Epidemiology of alcoholic liver disease in Korea. Jang JY, Kim DJ. Clin Mol Hepatol. 2018;24:93–99. doi: 10.3350/cmh.2017.0079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Non-invasive diagnosis of alcoholic liver disease. Mueller S, Seitz HK, Rausch V. World J Gastroenterol. 2014;20:14626–14641. doi: 10.3748/wjg.v20.i40.14626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Therapy for alcoholic liver disease. Jaurigue MM, Cappell MS. World J Gastroenterol. 2014;20:2143–2158. doi: 10.3748/wjg.v20.i9.2143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Definition, epidemiology and magnitude of alcoholic hepatitis. Basra S, Anand BS. World J Hepatol. 2011;3:108–113. doi: 10.4254/wjh.v3.i5.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ethnicity and health disparities in alcohol research. Chartier K, Caetano R. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887493/ Alcohol Res Health. 2010;33:152–160. [PMC free article] [PubMed] [Google Scholar]
- 23.Role of transcription factors in steatohepatitis and hypertension after ethanol: the epicenter of metabolism. Ansari RA, Husain K, Rizvi SA. Biomolecules. 2016;6:29. doi: 10.3390/biom6030029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Alcohol abuse and heart failure. Laonigro I, Correale M, Di Biase M, Altomare E. Eur J Heart Fail. 2009;11:453–462. doi: 10.1093/eurjhf/hfp037. [DOI] [PubMed] [Google Scholar]
- 25.Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Wong F, Bernardi M, Balk R, et al. Gut. 2005;54:718–725. doi: 10.1136/gut.2004.038679. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure - a review. Domurat ES, Elias AN. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637753/ J Natl Med Assoc. 1992;84:153–162. [PMC free article] [PubMed] [Google Scholar]
- 27.Predictive value of the model of end-stage liver disease in cirrhotic patients with and without spontaneous bacterial peritonitis. Kraja B, Sina M, Mone I, Pupuleku F, Babameto A, Prifti S, Burazeri G. Gastroenterol Res Pract. 2012;2012:539059. doi: 10.1155/2012/539059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.The effect of the first spontaneous bacterial peritonitis event on the mortality of cirrhotic patients with ascites: a nationwide population-based study in Taiwan. Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tseng KC. Gut Liver. 2016;10:803–807. doi: 10.5009/gnl13468. [DOI] [PMC free article] [PubMed] [Google Scholar]

